ASTH vs EXETF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASTH is a Sell and EXETF is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ASTH’s FA Score shows that 0 FA rating(s) are green whileEXETF’s FA Score has 2 green FA rating(s).
- ASTH’s FA Score: 0 green, 5 red.
- EXETF’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ASTH’s TA Score shows that 4 TA indicator(s) are bullish.
- ASTH’s TA Score: 4 bullish, 4 bearish.
Price Growth
ASTH (@Medical/Nursing Services) experienced а -5.19% price change this week, while EXETF (@Medical/Nursing Services) price change was -2.22% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.36%. For the same industry, the average monthly price growth was -0.59%, and the average quarterly price growth was +1612.96%.
Reported Earning Dates
ASTH is expected to report earnings on Feb 20, 2025.
EXETF is expected to report earnings on Feb 27, 2025.
Industries' Descriptions
@Medical/Nursing Services (-3.36% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ASTH | EXETF | ASTH / EXETF | |
| Capitalization | 1.88B | 459M | 410% |
| EBITDA | 124M | 57.3M | 216% |
| Gain YTD | 51.175 | 20.131 | 254% |
| P/E Ratio | 32.55 | 140.85 | 23% |
| Revenue | 1.39B | 1.24B | 112% |
| Total Cash | 296M | 105M | 282% |
| Total Debt | 321M | 397M | 81% |
ASTH | EXETF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 71 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 59 | 96 | |
SMR RATING 1..100 | 66 | 18 | |
PRICE GROWTH RATING 1..100 | 38 | 43 | |
P/E GROWTH RATING 1..100 | 71 | 86 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EXETF's Valuation (3) in the null industry is significantly better than the same rating for ASTH (71). This means that EXETF’s stock grew significantly faster than ASTH’s over the last 12 months.
ASTH's Profit vs Risk Rating (59) in the null industry is somewhat better than the same rating for EXETF (96). This means that ASTH’s stock grew somewhat faster than EXETF’s over the last 12 months.
EXETF's SMR Rating (18) in the null industry is somewhat better than the same rating for ASTH (66). This means that EXETF’s stock grew somewhat faster than ASTH’s over the last 12 months.
ASTH's Price Growth Rating (38) in the null industry is in the same range as EXETF (43). This means that ASTH’s stock grew similarly to EXETF’s over the last 12 months.
ASTH's P/E Growth Rating (71) in the null industry is in the same range as EXETF (86). This means that ASTH’s stock grew similarly to EXETF’s over the last 12 months.
| ASTH | |
|---|---|
| RSI ODDS (%) | 6 days ago 72% |
| Stochastic ODDS (%) | 6 days ago 85% |
| Momentum ODDS (%) | 6 days ago 81% |
| MACD ODDS (%) | 6 days ago 74% |
| TrendWeek ODDS (%) | 6 days ago 80% |
| TrendMonth ODDS (%) | 6 days ago 78% |
| Advances ODDS (%) | 8 days ago 79% |
| Declines ODDS (%) | 6 days ago 69% |
| BollingerBands ODDS (%) | 6 days ago 82% |
| Aroon ODDS (%) | 6 days ago 81% |
ASTH and
Correlation & Price change
A.I.dvisor indicates that over the last year, ASTH has been loosely correlated with PNTG. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ASTH jumps, then PNTG could also see price increases.
| Ticker / NAME | Correlation To ASTH | 1D Price Change % | ||
|---|---|---|---|---|
| ASTH | 100% | -4.44% | ||
| PNTG - ASTH | 43% Loosely correlated | -4.33% | ||
| USPH - ASTH | 42% Loosely correlated | -2.19% | ||
| HCSG - ASTH | 42% Loosely correlated | -3.11% | ||
| SGRY - ASTH | 41% Loosely correlated | -4.33% | ||
| NHC - ASTH | 41% Loosely correlated | -2.29% | ||
More | ||||
EXETF and
Correlation & Price change
A.I.dvisor tells us that EXETF and FSNUF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXETF and FSNUF's prices will move in lockstep.
| Ticker / NAME | Correlation To EXETF | 1D Price Change % | ||
|---|---|---|---|---|
| EXETF | 100% | -2.22% | ||
| FSNUF - EXETF | 28% Poorly correlated | N/A | ||
| AIRS - EXETF | 26% Poorly correlated | -2.70% | ||
| ASTH - EXETF | 23% Poorly correlated | -4.44% | ||
| INNV - EXETF | 23% Poorly correlated | -1.83% | ||
| THC - EXETF | 22% Poorly correlated | -4.05% | ||
More | ||||